摘要
目的:观察间苯三酚对先兆流产患者血清血红素氧合酶-1(HO-1)、孕激素诱导阻滞因子(PIBF)水平及临床症状的影响。方法:选取2020年1月-2022年2月新余市人民医院收治的84例先兆流产患者,按照随机数字表法将其分为两组,各42例。对照组给予黄体酮治疗,在此基础上,观察组给予间苯三酚治疗,连续治疗1周。比较两组治疗效果、临床症状改善时间、性激素水平、血清血红素氧合酶-1(HO-1),孕激素诱导阻滞因子(PIBF)水平及不良反应。结果:与对照组治疗总有效率比较,观察组较高(P<0.05)。与对照组止血时间、腹痛缓解时间、宫缩消失时间比较,观察组均较短(P<0.05)。治疗后两组人绒毛膜促性腺激素(β-hCG)及孕酮(P)均高于治疗前,与对照组比较,观察组均较高(P<0.05)。治疗后两组HO-1、PIBF均高于治疗前,且与对照组比较,观察组均较高(P<0.05)。治疗期间未发生严重不良反应。结论:间苯三酚可有效调节先兆流产患者HO-1、PIBF及性激素水平,促进患者临床症状的改善,提高治疗效果。
Objective:To observe the effect of Phloroglucinol on heme oxygenase-1(HO-1),progesteroneinducible blocking factor(PIBF)levels and clinical symptoms in patients with threatened abortion.Method:A total of 84 patients with threatened abortion who were admitted to Xinyu People's Hospital from January 2020 to February 2022 were selected,they were divided into two groups according to the random number table method,with 42 cases in each group.The control group was given Progesterone treatment,on this basis,the observation group was given Phloroglucinol treatment,continuous treatment for 1 week.The therapeutic efficacy,clinical symptom improvement time,sex hormone levels,HO-1,PIBF levels and adverse reactions were compared between the two groups.Result:The total effective rate in the observation group was higher than that in the control group(P<0.05).Compared with the control group,the time of hemostasis,abdominal pain relief and contraction disappearance were shorter in the observation group(P<0.05).After treatment,human chorionic gonadotropin(β-hCG)and progesterone(P)in both groups were higher than those before treatment,and compared with the control group,observation group were higher(P<0.05).After treatment,HO-1 and PIBF in both groups were higher than those before treatment,and compared with control group,the observation group were higher(P<0.05).No serious adverse reactions occurred during the treatment.Conclusion:Phloroglucinol can effectively regulate the levels of HO-1,PIBF and sex hormones in patients with threatened abortion,promote the improvement of clinical symptoms and improve the therapeutic effect.
作者
郭丽平
陈秋莲
陈琳
GUO Liping;CHEN Qiulian;CHEN Lin(Xinyu People's Hospital,Jiangxi Province,Xinyu 338000,China)
出处
《中国医学创新》
CAS
2023年第8期114-117,共4页
Medical Innovation of China